

Drivers of Socially Acceptable Costs in Outcomes Based Agreements and access

Van der Lelie LG¹, Yap EYS¹, Severens JL²



subject

New treatments like *gene therapy (GT)* often have uncertainties regarding effect, related to their (high) costs. Outcomes Based Agreements (OBA's) can reduce these uncertainties and can as such be

a solution towards access (figure 1). Lack of a broadly supported, general description for socially acceptable cost (SAC) can block implementation. Clear and predictable SAC (elements) can help

the industry to have realistic pricing strategies and can help payers to better substantiate their willingness to pay, preparing the way for agreement on the cost element of OBA's.

Fig. 1. How agreement on SAC and an OBA can facilitate access to new (expensive) therapies



research

2023 Survey amongst Payers (authorities, government, insurers) and Patients (organisations), market access Experts (scientific, reimbursement/HTA) and Industry (companies and umbrella organisations).

Which decisive elements are in your top-4 determining SAC for gene therapies in OBA?

results

Effect-related elements clear winner

All relevant stakeholders are represented in this convenience sample: Industry (37%), Experts (25%), Payers (19%) and Patients (19%). Respondents (n=57) are international, of which 64% is Dutch.

- 93% of respondents indicated effect related elements (i.e. *duration of effect, effect size, quality of life*) as most important (figure 2).
- The level of consensus between stakeholders seems lower for elements other than effect-related (figure 3).
- Trends on stakeholder top-elements:
 - Patients: disease related elements
 - Payers and authorities: profit related (e.g. *research and manufacturing cost and expected product profit*)
 - Industry: the *level of innovation* element

Fig. 2. Most important elements as mentioned overall
Y-axis: % of responders mentioning the (group of) elements





Fig. 3. (Dis)agreement between stakeholders per (group) of elements
Y-axis: 25% for all stakeholders is full consensus



conclusion

Other elements require stakeholder discussion to come to a general SAC description for GT

Effect-related elements are valued by all stakeholders as an important driver for SAC. There is more ambiguity on other SAC elements.

Implementation of OBA's and thus access can be facilitated by more mutual understanding, more discussion and, ideally, more stakeholder alignment on the importance and feasibility of all elements to describe SAC.

There may be disagreement on which stakeholders should be involved to develop the general SAC description.

follow up

Follow up Survey:
How to incorporate all relevant views, when developing a general description of socially acceptable costs? Agreeing on driver SAC-elements should be jointly discussed among relevant stakeholders.

Share your opinion in this short survey
Which relevant stakeholders should (not) be involved in developing a general SAC description?

